1. Home
  2. SXI vs ACAD Comparison

SXI vs ACAD Comparison

Compare SXI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standex International Corporation

SXI

Standex International Corporation

HOLD

Current Price

$300.49

Market Cap

3.5B

Sector

Industrials

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.58

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXI
ACAD
Founded
1955
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.8B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
SXI
ACAD
Price
$300.49
$25.58
Analyst Decision
Strong Buy
Buy
Analyst Count
3
22
Target Price
$289.67
$30.55
AVG Volume (30 Days)
230.9K
1.8M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
0.54%
N/A
EPS Growth
N/A
69.12
EPS
6.98
0.02
Revenue
$604,535,000.00
$726,437,000.00
Revenue This Year
$14.87
$18.80
Revenue Next Year
$6.07
$11.70
P/E Ratio
$43.93
$1,282.50
Revenue Growth
N/A
40.45
52 Week Low
$154.57
$19.69
52 Week High
$363.89
$28.35

Technical Indicators

Market Signals
Indicator
SXI
ACAD
Relative Strength Index (RSI) 45.21 62.29
Support Level $300.49 $25.40
Resistance Level $363.89 $27.79
Average True Range (ATR) 14.26 0.80
MACD -4.62 -0.08
Stochastic Oscillator 10.60 40.63

Price Performance

Historical Comparison
SXI
ACAD

About SXI Standex International Corporation

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: